Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Vaccines of the 21st Century

Université de Montréal

$98,222.00

Effect of sialic acid of Gram-positive bacteria capsular polysaccharides on the immunogenic capacity of conjugate vaccines

FY 2008-09

Summary
Vaccination helps to protect humans against virulent microbes, such as bacteria. Exposing individuals to bacterial components combined with an adjuvant that boosts immune responses is an effective vaccination strategy. A major challenge is the optimal manipulation of the immune system to generate effective immunity against pathogens. A key player orchestrating immune responses is the dendritic cell (DC), an immune cell type that senses and responds to microbes, thereby initiating and controlling the quality and strength of immune responses. As such, DCs are attractive modulatory targets for vaccine development. This proposal will address the role of DCs in generating a protective immune response to encapsulated bacteria, which are covered by a shell of sugars, known as the capsular polysaccharide (CPS), which helps bacteria to hide from the immune system. Antibodies to CPS are crucial for protection against infection; however, CPS is poorly immunogenic and sometimes composed of sugars which are also present in the human body. Thus, with CPS alone, the immune system does not mount an effective response. Fusion of CPS to a carrier protein (i.e. conjugate vaccines) enhances CPS immunogenicity and has resulted in substantial reduction of some bacterial infections in the developed world. However, disadvantages of CPS vaccines include the need for costly multiple doses, limiting their use in the developing world, and their disappointing efficacy in HIV+ patients and the elderly. Our proposal aims to dissect the effect of CPS sugar composition on the capacity of different conjugate vaccine preparations to activate DCs to efficiently mount a protective response. Supplementing vaccines with adjuvants that further increase DC recruitment/activity may provide an alternative strategy to improve CPS immunogenicity and reduce dose levels. Thus, research on DC interactions with CPS will reveal novel immunological targets for the development of new, more potent conjugate vaccines.
Program
Vaccines of the 21st Century
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
183442
Name
Segura Mariela A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant: Vaccines of the 21st Century
Projecttitle
Effect of sialic acid of Gram-positive bacteria capsular polysaccharides on the immunogenic capacity of conjugate vaccines
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$98,222
Cihrequipment2
$0
Programname2
Vaccines of the 21st Century
Keyworddelim
Capsular Polysaccharides; Dendritic Cells; Mhc-Ii Antigen Presentation; Sialic Acid; Streptococcus; T Cell Activation
Abstract
Vaccination helps to protect humans against virulent microbes, such as bacteria. Exposing individuals to bacterial components combined with an adjuvant that boosts immune responses is an effective vaccination strategy. A major challenge is the optimal manipulation of the immune system to generate effective immunity against pathogens. A key player orchestrating immune responses is the dendritic cell (DC), an immune cell type that senses and responds to microbes, thereby initiating and controlling the quality and strength of immune responses. As such, DCs are attractive modulatory targets for vaccine development. This proposal will address the role of DCs in generating a protective immune response to encapsulated bacteria, which are covered by a shell of sugars, known as the capsular polysaccharide (CPS), which helps bacteria to hide from the immune system. Antibodies to CPS are crucial for protection against infection; however, CPS is poorly immunogenic and sometimes composed of sugars which are also present in the human body. Thus, with CPS alone, the immune system does not mount an effective response. Fusion of CPS to a carrier protein (i.e. conjugate vaccines) enhances CPS immunogenicity and has resulted in substantial reduction of some bacterial infections in the developed world. However, disadvantages of CPS vaccines include the need for costly multiple doses, limiting their use in the developing world, and their disappointing efficacy in HIV+ patients and the elderly. Our proposal aims to dissect the effect of CPS sugar composition on the capacity of different conjugate vaccine preparations to activate DCs to efficiently mount a protective response. Supplementing vaccines with adjuvants that further increase DC recruitment/activity may provide an alternative strategy to improve CPS immunogenicity and reduce dose levels. Thus, research on DC interactions with CPS will reveal novel immunological targets for the development of new, more potent conjugate vaccines.
Competitiondate
200903
Approvedterm2
1 yr 0 mth
Pinamesdelim
Segura, Mariela A; Gottschalk, Marcelo G; Roy, René; Thibodeau, Jacques
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $98,222~ $0~
Université de Montréal - $98,222 Grant (2008-09) | Canada Spends